We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alliance to Develop HLA-Typing Method

By HospiMedica staff writers
Posted on 24 Oct 2001
A collaborative agreement to evaluate and develop methods for typing human leukocyte antigens (HLA) using a simple-to-use sequencing technology has been announced by Pel-Freez Clinical Systems LLC (Stockholm, Sweden) and the Molecular Diagnostics Business Unit of Pyrosequencing AB (Milwaukee, WI, USA). More...
The announcement was made at the conference of the American Society for Histocompatibility and Immunogenetics in San Francisco (CA, USA).

HLA genes are highly variable, which has a significant impact on patients undergoing organ and bone marrow transplantation. To achieve the highest clinical success, the goal in transplantation is to accurately match the patterns of HLA variability of the donor and patient. DNA-based method for HLA typing have enabled diagnostic labs to better identify appropriate donors. Pel-Freez and Pyrosequencing plan to base their new typing method on proprietary technology developed by Pyrosequencing. This technology is broadly applicable for the analysis of single nucleotide polymorphisms (SNPs) and for the identification and quantification of short DNA sequences used in bacterial and viral typing.

"We believe the Pyrosequencing platform will be truly novel in the HLA field with its ability to simultaneously deliver speed, resolving power, and versatility,” said Frank Langley, president of Pel-Freez.




Related Links:
Pyrosequencing
Pel-Freez

New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.